BioAtla^® is a biotech company developing novel monoclonal antibody and cell based therapeutics using their proprietary Conditionally Active Biologics^™ (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!^™) platforms. These and other proprietary technologies (protected by more than 150 issued patents and patent applications) allow the company to develop novel biologics (CABs) that are better drugs in multiple ways, including more selective targeting of cancer tissue and improved manufacturability. Improved selectivity for the tumor microenvironment (TME), even when the target is also found in normal tissue, not only improves safety and thus therapeutic index, but also expands the universe of potential drug targets, enabling the treatment of previously untreatable cancers.